LARS2 and cancer: In chronic lymphocytic leukemia, malignant cells exhibit a metabolic shift toward OXPHOS,366 with strategies targeting SIRT3 or OXPHOS showing promising antitumor efficacy.367 Specific molecular interactions, such as LARS2+ B-cell regulation by dietary leucine and the Erbin-mitochondria axis, offer insights into cancer progression and potential immunotherapeutic targets.368,369